Pediatric cGVHD Symptom Scale
NCT04044365
Recruiting
Background: Some children/adolescents who have had a stem cell transplant live with chronic graft-versus-host-disease (cGVHD). cGVHD is a side effect of the transplant that can cause multiple bothersome symptoms and negatively affect a child/adolescent squality of daily life. The questionnaires that measure thesymptoms caused by cGVHD are designed for adults. Children/adolescents may not describe their symptoms in the same way. The goal of this research is to improve the way we measure how both... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
08/07/2025
Locations: Children's Hospital Colorado (CHCO), Aurora, Colorado +12 locations
Conditions: Graft vs Host Disease
Register for Updates
Saddle Block With IT Morphine for Penile Inversion Vaginoplasty
NCT06556121
Recruiting
Penile Inversion Vaginoplasty (PIV) is a transition-related surgery (TRS) that is associated with severe postoperative pain. The optimal pain management strategies for this surgery remain unknown. We hypothesized that the addition of a saddle block with intrathecal morphine would yield clinically important analgesic benefits.
Gender:
MALE
Ages:
Between 18 years and 70 years
Trial Updated:
08/07/2025
Locations: Women's College Hospital, Toronto, Ontario
Conditions: Pain, Postoperative
Register for Updates
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
NCT03075696
Recruiting
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-into-human (EIH) study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Ingalls Memorial Hospital, Harvey, Illinois +37 locations
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population
NCT07043478
Recruiting
The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. The main question it aims to answer is: Is there a difference in the incremental area under the curve (iAUC) (from 0 - 120 mins following administration) for venous blood glucose between Bragg ACV liquid and placebo following an acute carbohydrate load. Participants will \[descr... Read More
Gender:
ALL
Ages:
Between 20 years and 50 years
Trial Updated:
08/07/2025
Locations: KGK Science Inc., London, Ontario
Conditions: Healthy, Blood Glucose
Register for Updates
Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons
NCT07122219
Recruiting
This study is focused on improving the implementation of Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons, with the goal of increasing the uptake of these programs among people who inject drugs in prison. The study is being conducted in nine federal prisons, including five women's prisons, where a higher proportion of incarcerated individuals report a history of injection drug use. This study aims to improve PNEP adoption and sustainability by identifying barriers and facilita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Edmonton Institution for Women, Edmonton, Alberta +8 locations
Conditions: HIV, Hepatitis C Virus (HCV)
Register for Updates
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777
Recruiting
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD). The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD. The study duration per participant will be up to 180 weeks, including: * A screening period of up to 2 to 4 weeks * An open label treatment period of up to 160 weeks (approximately 3 years) * A po... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/07/2025
Locations: Alabama Allergy & Asthma Center - Birmingham - Brookwood Boulevard- Site Number : 8400050, Birmingham, Alabama +189 locations
Conditions: Dermatitis Atopic
Register for Updates
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941
Recruiting
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/07/2025
Locations: Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona +53 locations
Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Register for Updates
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934
Recruiting
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: Research Site, Eden Prairie, Minnesota +25 locations
Conditions: ATTR Amyloidosis
Register for Updates
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT06881251
Recruiting
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: First OC Dermatology, Fountain Valley, California +70 locations
Conditions: Dermatitis, Atopic
Register for Updates
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
NCT06111586
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks Double-blind treatment period (104 weeks): * Main treatment period: 52 weeks * Blinded extension: 52 weeks Optional Open Label Extension: 104 weeks Safety follow-up:... Read More
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
08/07/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400012, San Francisco, California +73 locations
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
NCT06396416
Recruiting
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: London Health Sciences Centre, London, Ontario
Conditions: Obesity, Chronic Kidney Disease
Register for Updates
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +221 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates